

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

				Complete if Known	
<i>Application Number</i>	10/758,773				
<i>Filing Date</i>	January 16, 2004				
<i>First Named Inventor</i>	Seng H. CHENG				
<i>Art Unit</i>	1632				
<i>Examiner Name</i>	Shin-Lin Chen				
<i>Attorney Docket Number</i>	07680.0018-00000				

Sheet

1

of

2

U.S. PATENTS AND PUBLISHED U.S. PATENT APPLICATIONS					
Examiner Initials ⁵	Cite No. ¹	Document Number	Issue or Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code (if known)			
	1	US-5,179,023	01-12-1993	CALHOUN et al.	
	2	US-5,658,567	08-19-1997	CALHOUN et al.	
	3	US-5,834,266	11-10-1998	CRABTREE et al.	
	4	US-6,461,609	10-08-2002	CALHOUN et al.	
	5	US-6,492,332	12-10-2002	DEMOPULOS et al.	
	6	US-7,011,831	03-14-2006	CALHOUN et al.	

Note: Submission of copies of U.S. Patents and published U.S. Patent Applications is not required.

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials ⁵	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			Translation ⁶
	7	BUECHNER et al., "Central Nervous System Involvement in Anderson-Fabry Disease: A Clinical and MRI Retrospective Study," <i>J. Neurol. Neurosurg. Psychiatry</i> 79(11):1249-1254 (2008) (published online Jun. 5, 2008).			
	8	FELLGIEBEL et al., "CNS Manifestations of Fabry's Disease," <i>Lancet Neurol.</i> 5:791-795 (2006).			
	9	MEHTA et al. Eds., <i>Fabry disease Perspectives from 5 years of FOS</i> , Table of Contents pp. vii-x (Oxford PharmaGenesis™ Ltd., 2006).			
	10	MOORE et al., "The Cerebral Vasculopathy of Fabry Disease," <i>J. Neurol. Sci.</i> 257:258-263 (2007).			
	11	Office Action issued in parent U.S. Application No. 09/884,526, mailed May 29, 2003 (Attorney Docket No. 07680.0019-00000).			
	12	Office Action issued in parent U.S. Application No. 09/884,526, mailed February 18, 2004 (Attorney Docket No. 07680.0019-00000).			
	13	Office Action issued in parent U.S. Application No. 09/884,526, mailed August 25, 2004 (Attorney Docket No. 07680.0019-00000).			
	14	Office Action issued in parent U.S. Application No. 09/884,526, mailed January 31, 2005 (Attorney Docket No. 07680.0019-00000).			
	15	Office Action issued in parent U.S. Application No. 09/884,526, mailed August 10, 2005 (Attorney Docket No. 07680.0019-00000).			
	16	Office Action issued in parent U.S. Application No. 09/884,526, mailed March 6, 2006 (Attorney Docket No. 07680.0019-00000).			
	17	Office Action issued in parent U.S. Application No. 09/884,526, mailed October 17, 2006 (Attorney Docket No. 07680.0019-00000).			
	18	Office Action issued in U.S. Application No. 11/762,689, mailed September 25, 2008 (Attorney Docket No. 07680.0019-01000).			
	19	PALADIN LABS INC., "Conditional Approval of Replagal™ (agalsidase alfa): Fact Sheet" Paladin Labs Inc., February 6, 2004 (Health Canada). Available online at http://www.hc-sc.gc.ca/dhp-mps/prodpharma/notices-avis/conditions/replagal_fs_fd_068304-eng.php .			
	20	TSUJI et al., "Signal Sequence and DNA-Mediated Expression of Human Lysosomal α -Galactosidase A," <i>Eur. J. Biochem.</i> 165:275-280 (1987).			
	21	U.S. Food and Drug Administration, Department of Health and Human Services Approval Letter to Genzyme Corporation regarding U.S. License No. 1596, dated April 24, 2003 (available online at http://www.fda.gov/cder/foi/appletter/2003/agalgen042403L.htm).			

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

				Complete if Known
<i>Application Number</i>	10/758,773			
<i>Filing Date</i>	January 16, 2004			
<i>First Named Inventor</i>	Seng H. CHENG			
<i>Art Unit</i>	1632			
<i>Examiner Name</i>	Shin-Lin Chen			
<i>Attorney Docket Number</i>	07680.0018-00000			

Sheet

2

of

2

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		Translation ⁶
	22	ZARATE et al., "Lysosomal Storage Disease 3: Fabry's disease," <i>Lancet</i> 372:1427-1435 (2008).		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.